San Francisco, CA, United States of America

Elissa S Epel

This inventor holds 1 USPTO granted patent. Top assignee: University of California. Active years: 2017.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Elissa S Epel: Innovator in Mental Health Biomarkers

Introduction

Elissa S Epel is a prominent inventor based in San Francisco, CA. She has made significant contributions to the field of mental health through her innovative research and inventions. Her work focuses on understanding the biological markers associated with mood disorders, particularly major depression.

Latest Patents

Elissa S Epel holds a patent titled "Cell aging as a unique biomarker of major depression." This invention provides methods for determining whether a subject is a suitable candidate for anti-depressant treatment by measuring telomere length and telomerase activity. Additionally, it offers methods for assessing the efficacy of such treatments and predicting the risk of developing depression.

Career Highlights

Elissa is affiliated with the University of California, where she conducts her research. Her work has garnered attention for its potential to improve treatment strategies for mood disorders. She is recognized for her dedication to advancing the understanding of mental health through scientific innovation.

Collaborations

Elissa has collaborated with notable colleagues, including Owen M Wolkowitz and Synthia H Mellon. These partnerships have further enriched her research and contributed to the development of her patented methods.

Conclusion

Elissa S Epel's contributions to the field of mental health through her innovative patent highlight the importance of biological markers in understanding and treating mood disorders. Her work continues to pave the way for advancements in mental health research and treatment.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…